Last reviewed 2026-04-19 · How we verify

LACUDY

Gun Oh Chong · Phase 1 active Small molecule

LACUDY is a Small molecule drug developed by Gun Oh Chong. It is currently in Phase 1 development. Also known as: IC-LC02S2Q2.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LACUDY
Also known as	IC-LC02S2Q2
Sponsor	Gun Oh Chong
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LACUDY CI brief — competitive landscape report
LACUDY updates RSS · CI watch RSS
Gun Oh Chong portfolio CI

Frequently asked questions about LACUDY

What is LACUDY?

LACUDY is a Small molecule drug developed by Gun Oh Chong.

Who makes LACUDY?

LACUDY is developed by Gun Oh Chong (see full Gun Oh Chong pipeline at /company/gun-oh-chong).

Is LACUDY also known as anything else?

LACUDY is also known as IC-LC02S2Q2.

What development phase is LACUDY in?

LACUDY is in Phase 1.

Manufacturer: Gun Oh Chong — full pipeline
Also known as: IC-LC02S2Q2

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing